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Summary
Background: The potential benefit of silymarin (special ex-
tract from the fruits of Silybum marianum) in the treatment
of liver diseases remains a controversial issue. Methods:
For this systematic review electronic databases identified 65
papers for the search terms silymarin, silibinin, silicristin or
milk thistle and clinical trial. Only 19 complied with the crite-
ria ‘double-’ or ‘single-blind’. These publications were
analysed from a clinical point of view and meta-analytic cal-
culations were performed. Results: The clinical evidence of
a therapeutic effect of silymarin in toxic liver diseases is
scarce. There is no evidence of a favourable influence on
the evolution of viral hepatitis, particularly hepatitis C. In al-
coholic liver disease, comparing with placebo, aspartate
aminotransferase was reduced in the silymarin-treated
groups (p = 0.01) while alkaline phosphatase was not. In
liver cirrhosis, mostly alcoholic, total mortality was 16.1%
with silymarin vs. 20.5% with placebo (n.s.); liver-related
mortality was 10.0% with silymarin vs. 17.3% with placebo
(p = 0.01). Conclusions: Based on the available clinical evi-
dence it can be concluded – concerning possible risks /
probable benefits – that it is reasonable to employ silymarin
as a supportive element in the therapy of Amanita phal-
loides poisoning but also (alcoholic and grade Child ‘A’)
liver cirrhosis. A consistent research programme, consoli-
dating existing evidence and exploring new potential uses,
would be very welcome.
Schlüsselwörter
Silymarin · Silibinin · Mariendistel · Phytotherapie · Pflanz-
liches Arzneimittel · Leberzirrhose · Amanita phalloides · 
Alkoholische Hepatopathie · Radikalfänger
Zusammenfassung
Hintergrund: Der potentielle Nutzen von Silymarin (Spezial-
extrakt aus den Samen der Mariendistel, Silybum maria-
num) in der Behandlung von Lebererkrankungen wird kon-
trovers diskutiert. Methoden: Für diesen systematischen Re-
view fanden sich in elektronischen Datenbanken unter den
Suchbegriffen Silymarin, Silibinin, Silicristin oder Marien-
distel und klinische Studie 65 Publikationen. Nur 19 Studien
erfüllten die Zusatzkriterien ‘doppel-’ oder ‘einfachblind’.
Diese Publikationen wurden nach klinisch relevanten Ge-
sichtspunkten analysiert und metaanalytische Berechnun-
gen wurden durchgeführt. Ergebnisse: Die klinische Evidenz
der therapeutischen Wirkung von Silymarin bei toxischen
Leberschäden ist gering. Es gibt keine Daten, die auf eine
günstige Beeinflussung der Evolution von viralen Hepatiti-
den, insbesondere Hepatitis C, hinweisen würden. Bei alko-
holischen Leberschäden wurde mit Silymarin, im Vergleich
zu Placebo, eine Reduktion der Aspartat-Aminotransferase
erzielt (p = 0,01), nicht aber der alkalischen Phosphatase. Bei
Patienten mit meistens alkoholischer Leberzirrhose betrug
die Gesamtmortalität 16,1% mit Silymarin vs. 20,5% mit Pla-
cebo (n.s.); die leberbezogene Mortalität hingegen betrug
10,0% mit Silymarin vs. 17,3% mit Placebo (p = 0,01).
Schlussfolgerungen: Aufgrund der vorliegenden Evidenz
scheint die Verwendung von Silymarin sinnvoll bezüglich
wahrscheinlichem Nutzen / möglicher Risiken bei der unter-
stützenden Behandlung von Vergiftungen mit Amanita phal-
loides und von (alkoholischer und Child ‘A’) Leberzirrhose.
Ein systematisches Forschungsprogramm zur Konsolidie-
rung der bestehenden Evidenzen und zur Erforschung neuer
möglicher Anwendungen wäre wünschenswert.
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Introduction
Dating back to the time of the ancient Greeks (Theophrastus, 4th
century B.C.) and Romans (Pliny the Elder, 1st century A.D.), the
seeds of milk thistle (Silybum marianum, also known as St. Mary’s
thistle and lady’s thistle), have been used to protect liver health.
During the Middle Ages the seed of the milk thistle was also com-
monly used to treat liver diseases. Milk thistle grows up to 6 feet
tall, particularly well on sunny slopes in Mediterranean countries,
particularly Spain and Greece. The plant of the milk thistle
blooms from June through August, and the shiny black seeds are
harvested after the end of the summer to be used for medicinal
purposes.
The potential benefit of silymarin (extracted from the seeds of
Silybum marianum) in the treatment of liver diseases remains
controversial [1]. However, the drug continues to elicit great in-
terest in the scientific community, as reflected by more than 800
publications dealing with it, and it has a good safety record with
only rare case reports of gastrointestinal disturbances and allergic
skin rashes. The high prevalence of liver diseases such as chronic
hepatitis and cirrhosis and the high costs of current effective
treatments [2] emphasize the need for efficient and more cost-ef-
fective treatments.
The pharmacological data [3] show that silymarin possesses fairly
specific effects on cell-regulating mechanisms, beyond the well
known reactive oxygen species (ROS) scavenging properties con-
firmed in new studies indicating a potential to reduce toxic effects
of other drugs (e.g. cisplatin, amiodarone). These data could lead
to new and/or improved clinical applications of this drug al-
though, in our view, there are not enough dose-response data
available. There is consistent evidence that silymarin influences
the regulation of cell membrane permeability either by inhibiting
uptake, reducing cellular efflux or by stimulating it. Furthermore,
silymarin has been shown to inhibit various systems such as
leukotriene synthesis, the effects of tumour necrosis factor (TNF)
α and of other autacoids. In some models, silymarin was shown to
reduce the inducible nitric oxide synthetase-mediated production
of nitric oxide and to modulate the inflammatory immune re-
sponse already at low dose.
Although still unconfirmed, the interactions with P-glycoprotein,
multidrug resistance associated protein 1 and breast cancer resis-
tance protein, have attracted some interest since they may be ben-
eficial for the reversal of multi-drug resistance in cancer, increas-
ing the bioavailability and decreasing the clearance and possibly
the toxicity of drugs. Less controversial are the dermatologic UV-
protecting properties of silymarin which affords strong protection
against UV-induced damage including photocarcinogenesis. 
Milk thistle’s clinical efficacy is not as well studied and estab-
lished since the evidence is sometimes clouded by poor design
and reporting. While possible benefit has been shown most
 frequently, but inconsistently, for aminotransferases, survival and
other clinical outcomes have been studied less and with mixed
results [4]. The primary objective of this systematic review is  
to assess the efficacy and safety of silymarin, mainly from a
 clinical point of view and taking into account clinically relevant
end-points. It does not aim to replace future prospective trials
which shall provide ‘final’ evidence of the efficacy of silymarin,
but provide a quantified update due to meta-analysis of the 
‘status ubi’.
Methods
Search Strategy: Among the data sources consulted to identify trials for
this systematic review were bibliographic databases (TOXLINE, MED-
LINE, HealthSTAR, AIDSLINE, CANCERLIT, Embase, AMED,
Cochrane Col., PubMed, TOXMAP, TOXLINE Special, DART Special,
HSDB, IRIS, ITER, GENETOX, CHEMIDplus, Haz-Map), reference
lists from pertinent review articles and books, personal contacts with ex-
perts active in the area and manufacturers up to February 2007. All papers
were screened, and any dealing with prospective clinical trials were re-
tained for classification according to criteria described in an earlier paper
[5]. In the case of double publications, the authors retained those that
were most recent and/or had appeared in a peer-reviewed journal. All tri-
als rendered eligible were classified by indication and summarized in a
tabulated format by one reviewer (R.B.). The standard table included a
full reference, a quality rating, the type of pathology, demographic data
and treatments, end-points and adverse events (AE). The trials were
grouped by indication and by comparator. These tables were discussed
and verified with the other authors until consensus was reached. No for-
mal validation process was employed. The guidelines provided by the
Cochrane Collaboration Handbook for Reviews [6] have been applied in
the analysis of the clinical data. For the meta-analysis significances were
calculated using 2-sided tests, the threshold of significance being p ≤ 0.05
and for non-significance p > 0.1; values between p > 0.05 and p ≤ 0.1 were
reported as trends.
Results
We found 860 papers of which 53 (n = 16 from the past 5 years
since our last review) also complied with the descriptor ‘clinical
trial’, but only 19 were ‘double-blind’ (n = 11; 4 of them from the
past 5 years) or ‘single-blind’ (n = 8). 12 additional clinical studies
were identified through other channels. In the following the re-
sults are presented according to clinical features. 
Pharmacokinetics of Silymarin
The bioavailability of silibinin (INN), deemed the main active
flavonolignan of silymarin (milk thistle extracts from seeds), is
low [7] and seems to depend on several factors such as: (a) the
content of accompanying substances with a solubilizing character
such as other flavonoids, phenolics, aminoacids, proteins, toco-
pherol, fat, cholesterol and others found in the extract, and (b) the
concentration of the extract itself. The systemic bioavailability can
be enhanced by adding solubilizing substances or carriers such as
phosphatidylcholine and β-cyclodextrin and possibly by the
choice of the capsule material [8–12]. The variations in content,
dissolution and (oral) bioavailability of silibinin between different
commercially available silymarin products are significant [13], in
spite of the same declaration of content. Although systemic plas-
ma levels are irrelevant if the site of action of silibinin is the liver,
these are usually measured for accessibility reasons, as they
should reflect the quantity of the drug being absorbed from the
gastrointestinal tract. Adequate bioavailability accounts for dose-
related oral activity of silymarin in the liver.
Silibinin was tested ‘in vitro’ for inhibition of human cytochrome
P-450 enzymes in concentrations of 3.7–300 µM. Clear inhibition
was only found for denitronifedipine oxidation (CYP3A4; IC50 =
29 µM) and S(-)-warfarin 7-hydroxylation (CYP2C9; IC50 = 43
µM) [14]. When additional substrate concentrations were tested
to assess enzyme kinetics, silibinin was a potent competitive in-
10 Forsch Komplementärmed 2008;15:9–20 Saller/Brignoli/Melzer/Meier
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hibitor of dextromethorphan metabolism at the low affinity site,
which is not CYP2D6 (Ki,c = 2.3 µM and 2.4 µM). Inhibition was
competitive for S(-)-warfarin 7-hydroxylation (Ki,c = 18 µM and
19 µM) and mainly non-competitive for denitronifedipine oxida-
tion (Ki,n = 9 µM and 12 µM). Silibinin and its beta-glycosides did
not interfere with the expression of CYP1A2 and CYP3A4 in
human hepatocytes [15], and were considered unlikely to produce
drug-drug interactions in terms of inducibility of these cy-
tochromes.
With therapeutic silibinin peak plasma concentrations of 0.6 µM
and biliary concentrations up to 200 µM it was concluded [14] that
metabolic interactions with xenobiotics metabolised by CYP3A4
or CYP2C9 cannot be excluded, a view not shared by others [17].
No interactions have been described in humans so far; silymarin
160 mg tid (3 × daily) had no apparent effect on indinavir plasma
concentrations, a potent inhibitor of CYP3A3/4 [18, 19] with the
possible exception of a 25% decrease of mean trough levels [20].
In a recent study [21], 200 mg silymarin tid, for 14 consecutive
days, did not affect the function of CYP3A4 and UGT1A1 in can-
cer patients treated with irinotecan. Following milk thistle admin-
istration (900 mg daily during 14 days) [22], digoxin AUC0–24
showed a small decrease (–9.4%; p = 0.06), thus suggesting that it
is not a potent P-glycoprotein-modulator ‘in vivo’. The adminis-
tration of a single dose of silibinin does not modify the kinetics of
alcohol [23]. 
In men, after single oral administration of a standardised dose of
100–360 mg silibinin, peak plasma levels were reached after ap-
proximately 2 h and ranged between 200 and 1,400 ng/ml silibinin,
of which approximately 75% was presented in the conjugated
form [24, 25]. For total silibinin, an elimination half-life of approx-
imately 6 h is estimated [26]. 3–8% of an oral dose is excreted in
the urine [27], while 20–40% is recovered from the bile as glu-
curonide and sulphate conjugates [28, 29]. The remaining part is
excreted via faeces (unchanged, not absorbed). Silibinin levels in
bile reach approximately 100 × higher concentrations than in
serum (10–5 to 10–4 mol/l of silibinin in bile), with peak concentra-
tions within 2–9 h. Biliary excretion continues for 24 h after a sin-
gle dose. No accumulation is observed after multiple dosing. In
cirrhotic patients, as compared to healthy volunteers, plasma lev-
els (120 ng/ml after a dose of 360 mg silibinin) were somewhat
lower and tmax (2.6 h) slightly delayed [30, 31]. The AUC suggest
that extrahepatic biliary obstruction is associated with a reduced
clearance of conjugated silibinin.
Poisoning with Amanita phalloides 
The Amanita phalloides mushroom (‘death cap’) has been known
and feared for at least 2 millennia and continues to cause serious
illness and death. Of the many cytotoxins produced by mush-
rooms, the most important is the potent amanitin found in some
mushrooms belonging to the genera Amanita and Galerina.
Amanitin is a cyclic octapeptide which inhibits RNA polymerase
II, thus interfering with protein synthesis. Phalloidin, a cyclic hep-
tapeptide that accompanies amanitin and may interfere with actin
polymerization, is probably responsible for the initial gastroin-
testinal symptoms. Amanita phalloides intoxications are not very
frequent. 
Symptoms of amanitin poisoning appear from 6–24 h after inges-
tion, starting with abdominal pain, followed by severe vomiting,
diarrhoea and fever. After 1–2 days, the gastrointestinal symp-
toms abate but at this stage, serum levels of aminotransferases
may begin to rise [32, 33]. Significant amounts of Amanita toxin
can be detected in gastroduodenal fluid even at 48 h after inges-
tion, suggesting an enterohepatic circulation [34].
There have been no reported controlled trials of the various treat-
ments suggested for mushroom poisoning. Toxins should be elim-
inated from the digestive tract as soon as possible by gastric
lavage and subsequent administration of activated charcoal.
 Penicillin (300,000–1,000,000 U/kg/day) and silibinin (20–50 mg/
kg/day) have been reported to be effective against amanitin poi-
soning. Anecdotal and animal studies also suggest a potential
benefit of cimetidine, aucubin (an iridoid glycoside of Aucuba
japonica), and kutkin. Haemodialysis has been used to treat acute
renal failure, but this procedure does not remove the toxin, which
is rapidly fixed in tissues [29].
Silibinin is considered to be the main active isomer of silymarin.
Consequently, and for the purposes of completeness, the results
obtained with intravenous silibinin in the therapy of mushroom
poisoning are also briefly presented here. Pharmacologically, the
use of silibinin appears to be justified as described in our publica-
tion on pharmacology [3]. On some occasions, oral silymarin has
been used as a substitute for silibinin or for maintenance treat-
ment [35]. 
In case series produced before 1970, mortality varied between 30
and 46% (mean 31%); in the period 1974–80, mortality varied be-
tween 0 and 26% (mean 11.4%). Detailed case control studies
dealing with patients not treated with silibinin / silymarin, show
an overall mortality of 18.3%, with a trend towards a decreasing
mortality over time [33], and the most recent reports still show a
mean mortality of 12.8% [36]. The entire series of case control
studies with silibinin / silymarin show an overall mortality of
9.8%, falling to <8% if only the last 15 years are taken into ac-
count. An analysis based on 154 cases of intoxication with Amani-
ta phalloides reported in Germany from 1983–1992 [37], showed a
mortality of 15.2% in 38 not silibinin-treated cases vs. 8.3% in the
remaining, silibinin-treated patients. However, the dose of amani-
ta, time between ingestion and treatment and other factors might
have been different. The daily dose of silibinin was ≤ 20 mg/kg
day in 53.2% of the cases and up to 50 mg/kg day in 31.8% of the
cases. Treatment duration was 4–5 days in most cases. Silibinin or
silymarin, eventually combined with N-acetylcysteine, continue to
represent the therapeutic mainstay in the therapy of the intoxica-
tions with Amanita phalloides [38].
Silymarin in Other Toxic and Iatrogenic Liver Diseases
In spite of the large number of animal pharmacology studies, the
study-based clinical evidence of a therapeutic effect of silymarin
in toxic liver diseases other than mushroom poisoning is scarce,
mostly outdated and frequently of poor quality. More than 20
years ago, 2 open comparative studies examined silymarin in the
treatment of liver diseases in workers exposed to hepatotoxic in-
dustrial solvents, describing improvement in liver function tests
[39, 40].
Several studies dealt with iatrogenic liver diseases. 2 older trials
have investigated whether silymarin could inhibit the liver en-
zyme increase observed after cholecystectomy in patients anaes-
thetized with either Halothane [41] or with Fentanyl [42]. While
Forsch Komplementärmed 2008;15:9–20Clinical Evidence of Silymarin 11
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the former was incompletely reported but nonetheless showed
some inhibitory effect on the postsurgical aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) increases, the
latter was entirely excluded from further analysis due to lack of
randomisation and incomplete reporting of data. 
Other trials dealt with the prevention of hepatic disorders caused
by neuroleptics. In 1 early trial [43], silymarin was associated with
an improvement of mean AST and ALT values but the compara-
bility of the two groups is questionable. A not significant reduc-
tion in the AST and ALT levels was reported [44] in female pa-
tients treated with phenothiazines or butirophenones with sily-
marin, but the malondialdehyde levels decreased by approxi-
mately 18% (p < 0.001). 
Only 1 study [45] complies with modern standards of design and
reporting. This 12-week randomised double-blind placebo-con-
trolled study on 222 out-patients suffering from mild-to-moderate
dementia of the Alzheimer type, was set up to assess the ability of
silymarin to antagonise or prevent the hepatotoxic effects of
tacrine. Silymarin was started first (1 week) and tacrine was then
added at 40 mg/day for 6 weeks, then increased to 80 mg/day (6
weeks). Although no statistical difference was observed for serum
ALT (the main evaluation criterion), unwanted effects and no-
tably gastrointestinal complaints were less frequent in the sily-
marin group: the incidences of AEs rated as possibly treatment-
related were: silymarin + tacrine = 9.5% vs. placebo + tacrine =
23.6% (p = 0.01). This study was too short to detect an eventual
beneficial outcome on the dementia, as reported for other antiox-
idants [46].
Viral Hepatitis
All 5 known types of viral hepatitis (A to G) cannot be distin-
guished reliably by clinical features or routine laboratory tests.
The specific aetiology of viral hepatitis is determined by serologi-
cal testing. Chronic hepatitis does not occur after hepatitis A or E.
It ensues in 1–5% of cases of acute hepatitis B virus (HBV) infec-
tion and 85% of cases of acute hepatitis C virus (HCV) infection
[47].
In patients with chronic hepatitis B, treatment with interferon
alpha (IFN-α) and the resulting loss of hepatitis Be antigen
(HBeAg) from the blood, leads to a reduction in inflammatory
activity and is associated with improved clinical outcome [48].
Recommended therapies include long-term treatment with
lamivudine for chronic hepatitis B, treatment of hepatitis C and
hepatitis D with IFN [49]. Treatment of HCV with IFN-α has
been disappointing, but new therapies (e.g. pegylated IFN-α) and
treatment schemes combining with ribavarin have led to an im-
proved suppression of HCV RNA levels [50, 51]. Although sily-
marin is not known to affect viral replication, from a pharmaco-
logical perspective, it might be expected to inhibit the inflamma-
tory and cytotoxic cascade of events triggered by the viral infec-
tion.
4 trials were conducted in the 1970s and are of historical interest
only [52–55]. Lirussi and Okolicsanyi [56] compared silymarin
and ursodeoxycholic acid (UDCA) in a rather heterogeneous
population of patients with ‘active cirrhosis‘, the majority of
which were HCV-positive. No efficacy was shown in this study
with inadequate reporting of statistics. More recently, a new silib-
inin complex (IdB1016 240 mg of silibinin 2 × daily) was studied
in a short-term placebo-controlled pilot study on 20 patients with
chronic active hepatitis, showing reduction of the AST concentra-
tions but no consistent differences in the other liver function tests
[57]. 
3 studies have been clearly negative. Huber et al. [58] retrospec-
tively investigated the effects of silymarin on aminotransferase
levels in 40 patients with chronic hepatitis C, not eligible for treat-
ment with pegylated IFN and ribavirin, treated with 420 mg, 840
mg or 1,260 mg per day during 125 ± 78 days. Aminotransferase
levels were determined before, during and at the end of treat-
ment. ALT, AST and gamma glutamyltransferase (GGT) levels
did not change significantly from baseline in any dose-group.
Recently, 2 double-blind trials evaluated silymarin for preventing
complications of chronic HCV infection [59, 60]. In the first trial
177 consenting residents of an Egyptian village were included
(Egypt has the highest prevalence of HCV infection in the world,
averaging 15–25% in rural communities). They were randomly as-
signed to receive either silymarin (124.5 mg tid) or a low-dose
multivitamin supplement deemed to be a placebo. Community
nurses visited weekly to ascertain compliance, distribute supple-
ments and record AEs. At 12 and at 24 months, almost all of 141
remaining subjects reported feeling better, although symptoms
and quality of life (QoL) scores (Short Form 36 – SF 36) did not
differ between the silymarin and the multivitamin group. Serum
ALT elevations, serum hepatic fibrosis marker (hyaluronic acid
and YKL-40, a growth factor participating in inflammation and
remodelling of the extracellular matrix), and abdominal ultra-
sound results were similar in both groups and the latter may have
progressed slightly. 
El-Zayadi et al. [61] studied 170 naive hepatitis C patients, also in
Egypt, with elevated ALT (>1.5-fold) and detectable HCV which
could not afford IFN-based therapy. They were randomly allocat-
ed to either group I (n = 87; biopsy proved chronic hepatitis in 62)
who were administered a daily combination of ribavirin (600–800
mg) plus amantadine (200 mg) and UDCA (500 mg) for 24 weeks,
or to group II (n = 83) who were administered silymarin 450
mg/day for 24 weeks. Normalization of ALT at the end of treat-
ment was achieved in 58.5 and 15.3% of the patients, whereas
end-of-treatment virologic response (ETVR) was achieved in 2.4
and 0% of group I and II, respectively. While this study was not
placebo-controlled, it confirmed earlier trials in that little or no
benefit was afforded by the silymarin treatment in hepatitis C.
In a small double-blind, placebo-controlled, crossover pilot trial
reported by Gordon et al. [62], patients (n = 24, completed n = 17)
received 12 weeks of S. marianum (either 600 mg or 1,200
mg/day) and placebo separated by a 4-week washout interval. S.
marianum was well tolerated in subjects with chronic hepatitis C,
but did not significantly affect serum HCV RNA, ALT levels,
QoL or psychological well-being (SF-36, State-Trait Anxiety In-
ventory) of the patients.
Alcoholic Liver Disease
The available data [63] show the induction of free radicals by
ethanol to be a complex interactive process. The classical path-
way for ethanol metabolism, catalyzed by alcohol dehydrogenase
to form acetaldehyde, leads to the formation of free radicals, re-
sulting from concomitant changes in reduced nicotinamide ade-
nine dinucleotide (NADH) levels and NADH/NAD+ redox ra-
12 Forsch Komplementärmed 2008;15:9–20 Saller/Brignoli/Melzer/Meier
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tios, which in turn modulate the activity of the free radical gener-
ating enzyme xanthine oxidase. The induction of CYP2E1 in the
microsomes leads to the generation of hydroxyethyl radicals, an-
other major route by which ethanol induces free radical forma-
tion. In addition to the above, ethanol may also induce free radi-
cal formation via the reaction of aldehyde oxidase with acetalde-
hyde or NADH to generate oxyradicals via disturbance in the me-
tabolism of the pro-oxidant iron, or via increased efflux from
mitochondria following altered mitochondrial oxidative metabo-
lism. Likewise, pancreatic stellate cells are activated ‘in vitro’ on
exposure to ethanol with generation of oxidant stress within the
cells [64]. However, until consistent evidence of a relation be-
tween the induction of free radicals and the prognosis of these
patients is available, thus eventually justifying their use as surro-
gate end-points, the clinician will be forced to continue using clin-
ical predictors of outcome and classical end-points when evaluat-
ing the therapeutic value of a treatment. Clinical and laboratory
features are powerful prognostic indicators for short-term mortal-
ity. Hepatic encephalopathy, derangement in renal function, hy-
perbilirubinaemia, and prolonged prothrombin time are seen
more frequently in patients who succumb to their illness than in
those who survive. Long-term survival in patients with alcoholic
hepatitis who discontinue alcohol is significantly better than in
those who continue to drink, although it remains considerably
below that of an age-matched population. 3-year survival ap-
proaches 90% in abstainers, whereas it is <70% in active drinkers
[65].
In a double-blind study on patients with chronic alcoholic liver
disease [66], a 6-month treatment (at a daily dose of 420 mg) with
silymarin significantly restored the superoxide dismutase activity
of erythrocytes and lymphocytes, the serum level of free-SH
groups and the activity of glutathione peroxidase. 
Silymarin has been studied most exhaustively in alcohol-induced
liver diseases with the largest number of studies and patients.
Such diseases have been classified, somewhat arbitrarily, for the
purposes of this review, into 2 main chapters: (1) alcohol-induced
liver diseases (in principle excluding cirrhosis) with mainly bio-
chemical end-points, (2) liver cirrhosis (mostly alcohol-induced)
with clinical end-points as primary criteria.
Alcohol-Induced Liver Diseases
Fintelmann et al. [67] published the first double-blind placebo-
controlled study with silymarin in alcohol-induced liver disease.
There was no diagnostic work-up and the reporting did not com-
ply with modern criteria. The graphics presented in that paper
show significant differences in favour of the active therapy at day
28 on AST and ALT, but not significant on GGT nor alkaline
phosphatase (AP). A second study in 1981 reported that the
symptoms of dyspepsia, asthenia, anorexia and nausea were all
significantly improved with silymarin, while only dyspepsia im-
First Disease Treatment Control Weight WMD 95% CI
 author studied
n mean (sd) n mean (sd)
Pares Cirrhosis 96 58.00 (37.00) 89 50.00 (34.00) 3.69 8 –2.23, 18.23
Bunout Cirrhosis 34 31.91 (9.20) 37 25.40 (6.60) 27.45 6.51 2.76, 10.26 
DiMario Alcoh. liv. dis. 15 25.40 (15.60) 14 50.60 (24.30) 1.72 –25.2 –40.18, –10.22
Feher Alcoh. liv. dis. 17 22.80 (5.10) 19 31.30 (4.50) 38.78 –8.5 –11.66, –5.34 
Muzes Alcoh. liv. dis. 10 28.00 (11.00) 20 52.00 (13.00) 4.9 –24 –32.88, –15.12 
Salmi Alcoh. liv. dis. 47 38.20 (15.99) 50 51.20 (24.99) 5.61 –13 –21.30, –4.70 
Trinchet Cirrhosis & 57 57.00 (15.00) 59 53.00 (10.00) 17.84 4 –0.66, 8.66 
Alcoh. liv.dis.
Total 276 288 100 –2.84 –4.81, –0.87
Test for heterogeneity: Chi² = 84.89, df = 6 (p < 0.00001), I² = 92.9%.
Test for overall effect: Z = 2.83 (p = 0.12).
For fixed effect model, test for overall effect: Z = 2.83 (p = 0.005).
After excluding cirrhosis only trials (Bunout and Pares):
Test for heterogeneity: Chi² = 44.04, df = 4 (p < 0.00001), I² = 90.9%.
Test for overall effect: Z = 2.52 (p = 0.01). 
For fixed effect model, test for overall effect: Z = 5.91 (p < 0.00001).
Table 1. Weighted
mean differences
(WMD) in AST
 levels at the end of
trials (WMD, random
model) dealing with
alcoholic liver disease
or cirrhosis
First Disease Treatment Control Weight WMD 95% CI
 author studied
n mean (sd) n mean (sd)
Pares Cirrhosis 96 206.00 (116.00) 89 189.00 (124.00) 19.8 17 –17.67, 51.67
Bunout Cirrhosis 34 207.00 (14.00) 37 196.00 (9.40) 34.53 11 5.40, 16.60
DiMario Alc. liv. dis. 15 145.00 (58.00) 14 177.00 (78.00) 13.34 –32 –82.31, 18.31
Feher Alc. liv. dis. 17 144.00 (17.00) 19 164.00 (19.00) 32.33 –20 –31.76, -8.24
Total 165 162 100 –3.57 –26.87, 19.73
Test for heterogeneity: Chi² = 24.31, df = 3 (p < 0.0001), I² = 87.7 %.
Test for overall effect: Z = 0.30 (p = 0.76).
Table 2. AP levels
at the end of trials
(WMD, random
model) dealing with
alcoholic liver disease
or cirrhosis
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proved significantly with placebo [68]. In that study, there was a
significant difference in favour of the silymarin-treated group at
the end of treatment with regard to AST and ALT, but not with
regard to total bilirubin, AP, cholesterolaemia and albuminaemia.
Prothrombin time was 91.7 ± 8.4% in the silymarin-treated group
vs. 80.6 ± 29.2% in the placebo group (not significant, n.s.). 
In what is probably the best study in this chapter from a qualita-
tive perspective, Salmi and Sarna [69] studied 106 patients with
mild acute and subacute liver disease, of which 90 had histological
diagnosis. They were selected on the basis of elevated serum
transaminase levels. Alcohol was forbidden during the trial. The
patients were randomly allocated into a group treated with sily-
marin and a group receiving placebo. A significantly larger de-
crease of ALT and AST was noted in the verum group vs. con-
trols. Serum total and conjugated bilirubin did not show differ-
ences. In the sub-populations examined, bromosulphalein (BSP)
retention test and histological changes returned to normal more
frequently with silymarin (p = 0.035 and p = 0.022, respectively). 
The effects of silymarin therapy on liver function tests, serum pro-
collagen III peptide level and liver histology were studied in 36
patients with chronic alcoholic liver disease in a 6-month double-
blind clinical trial [70]. During silymarin treatment, serum biliru-
bin, AST and ALT values normalised and GGT activity and pro-
collagen III peptid level decreased. The differences between the 2
groups were significant at the end of the observation period. At
the end of treatment, no differences on total protein, albumin, or
globulin were found between groups; plasmatic prothrombin lev-
els were 95 ± 4% in the silymarin-treated group and 86 ± 4% in
the placebo-treated group (n.s.). Regrettably, this publication did
not provide adequate reporting of study flow, dropouts or AEs.
The pooled analysis of the studies briefly outlined above can be
summarized as follows: 
Although there were no clinical end-points, histological findings
were reported as improved in 2 out of 2 trials but only a part of
the patients had control histology. BSP retention test is reported
in 1 trial as significantly better after silymarin. 
The improvement of prothrombin time becomes significant if tri-
als are combined (weighted mean at end of treatment, silymarin
92.3 ± 5.2% vs. placebo 84.3 ± 10.7%; 2 trials). 
After treatment, the enzyme levels were heterogeneous between
trials, AST was lower in the silymarin-treated groups (p = 0.01)
while AP was not (tables 1, 2). 
The evolution of ALT, GGT and of bilirubin values was not as-
sessable due to differences at baseline. 
2 major open trials have been reported [71, 72]; they may help to
complete the picture from the perspective of daily practice, par-
ticularly concerning the rates of disappearance of symptoms such
as tiredness (52.1%), epigastric discomfort (59.6%), lack of ap-
petite (67.6%), nausea (78.6%) or pruritus (72.3%). In a small
trial [73], 30 patients affected by chronic ethylic hepatopathy were
treated with 450 mg/daily of UDCA; after 6 months, a significant
decrease of serum hepatic enzymes was noted. The addition of
silymarin (400 mg/daily) to UDCA in other 30 patients induced a
further improvement of hepatic function.
Liver Cirrhosis
Liver cirrhosis is the relatively frequent final common pathology
of non-alcoholic or alcoholic fatty liver disease and chronic he-
patitis (HBV, HCV). The treatments for the underlying causes are
of limited efficacy. In the case of chronic HBV, IFN is the pre-
14 Forsch Komplementärmed 2008;15:9–20 Saller/Brignoli/Melzer/Meier
ferred treatment in patients with well-compensated cirrhosis
(Child’s A and B) while lamivudine is a safer therapy for patients
with more advanced cirrhosis [74].
Tools that have been proven useful in the prediction of survival in
patients with chronic liver disease include the Child-Pugh classifi-
cation and the degree of ascites [75]; that is, patients with ascites
unresponsive to diuretics have <50% chance of surviving 1 year
without transplantation [76].
Clinical trials in liver cirrhosis are complicated by a series of con-
founding factors which may make it difficult to show an effect.
The following factors seem particularly relevant: (1) persistence
of ‘offending’ factors (e.g. alcoholism, viral infection, etc.), (2)
concomitant therapies such as supportive treatments or corticos-
teroids, (3) compliance of the patients (known to be a major
problem in alcoholics), etc.
The pharmacological rationale for using silymarin in this indica-
tion(s) is fairly broad. The inhibition of the 5-lipoxygenase path-
way, particularly leukotriene B4 (LTB4), the ROS scavenging
properties of the compound, the inhibition of activation of NF-κ
B, kinases and caspases may explain its role in cytoprotection. In 1
placebo-controlled study [77] with patients suffering from alco-
holic cirrhosis (n = 60), silymarin (150 mg tid) increased total Glu-
tathione (GSH) at 6 months by 29% (p < 0.001) and platelet-de-
rived non-induced malondialdehyde decreased by 33% (p <
0.015). A parallel decrease in N-terminal propeptide of type III
collagen values (PIIINP, which has been investigated for assessing
and monitoring fibrotic processes in liver diseases, thus avoiding
the need for liver biopsies) was seen with silymarin, but values
were not comparable at baseline. There were no concurrent
changes on laboratory indices of the pathology, which makes the
assessment of the relevance of these findings somewhat difficult.
The study by Ferenci et al. [78] was performed to determine the
effect of silymarin on the outcome of patients with cirrhosis. This
randomised controlled trial (RCT) was performed on 170 patients
with cirrhosis of which 87 were treated with 140 mg silymarin tid
(alcoholic: 46, non-alcoholic: 41) and 83 received a placebo (alco-
holic: 45, non-alcoholic: 38). The mean observation period was 41
months. There were 10 dropouts in the placebo group and 14 in
the treatment group (mostly non-compliance). In the placebo
group, 37 (+2 dropouts) patients had died; 31 of these deaths were
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Fig 1. Summary of clinical indications and supporting evidence.
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related to liver disease. In the treatment group, 24 (+4 dropouts)
had died, and 18 of these deaths were related to liver disease. The
4-year survival rate was 58% in silymarin-treated patients and
39% in the placebo group (p = 0.036). Analysis of subgroups indi-
cated that treatment was effective in patients with alcoholic cir-
rhosis (p = 0.01) and in patients initially rated ‘Child A’ (p = 0.03).
Trinchet et al. [79] conducted a randomised double-blind trial of
silymarin vs. placebo in 116 patients with histologically proven al-
coholic hepatitis, 58 of them with cirrhosis. 57 patients received
silymarin orally 420 mg/day and 59 received placebo during 3
months. Biological parameters were assessed in the serum and a
percutaneous liver biopsy was obtained both at the start of the
trial and, in some of the patients, after 3 months. The 2 therapeutic
groups were comparable at inclusion. 26% of patients were lost to
follow-up at 3 months. Abstinence was obtained in 46% of pa-
tients at the end of the trial. 4 patients died during the trial, all of
hepatic failure, 1 under silymarin vs. 3 in the placebo group (not
specified whether having alcoholic hepatitis or cirrhosis, therefore
the entire population was included in the meta-analysis). Signifi-
cant improvement in the score of alcoholic hepatitis and serum
aminotransferase activity was noted in both groups during the
trial, irrespective of treatment with silymarin or placebo but clear-
ly correlated with abstention from alcohol. The authors concluded
that ‘silymarin 420 mg/d is not clinically relevant in the treatment
of moderate alcoholic hepatitis’.
Bunout et al. [80] conducted a controlled trial on the use of sily-
marin in patients with alcoholic cirrhosis. 71 patients were ad-
mitted to the trial and randomly assigned to an experimental or
control group. The verum group (n = 34) received a relatively
low dose of 280 mg/day of silymarin, controls (n = 37) received
an equal number of placebo tablets. Both groups did not differ
in their initial laboratory assessment and were followed up for
an average of 15 months. 10 patients died during the follow up (5
in placebo and 5 in silymarin; liver-related death in 9). No details
concerning distribution by therapeutic group are provided. No
significant differences were observed between these 2 groups. It
was concluded that silymarin did not change the evolution or
mortality of alcoholic liver disease in this trial.
The trial by Velussi et al. [81] is a 12-month open, controlled study
which was conducted in 2 well-matched groups of insulin-treated
diabetics with alcoholic cirrhosis, abstaining from alcohol for at
least 2 years prior to the study (randomisation not specified). 1
group received 600 mg silymarin per day plus standard therapy,
while the control group received standard therapy alone. Since
the authors, in addition to the metabolic variables which shall be
discussed in more detail under complications of cirrhosis, also re-
ported about deaths and other clinical outcomes, it was decided to
incorporate this trial in the meta-analysis.
The double-blind multi-centre RCT by Pares et al. [82] specifical-
ly aimed at determining the effect of silymarin (150 mg tid) in al-
coholics with liver cirrhosis with respect to survival and clinical
and laboratory changes. They enrolled 200 alcoholics with histo-
logically (n = 191) or laparoscopically (silymarin = 6 cases, place-
bo = 3 cases) proven liver cirrhosis. The primary outcome was
time to death, and the secondary outcome was the progression of
liver failure. Additional analyses identified 75 patients with HCV
antibodies. 103 patients were assigned to receive silymarin and 97
to receive placebo. The 2 groups were well matched for demo-
graphic and baseline clinical and laboratory features. There were
185 assessable patients and 125 (silymarin = 57, placebo = 68)
completed a 2-year study period. 42 patients left the trial during
the 2-year period (silymarin = 29, placebo = 13; mostly non-com-
pliance, voluntary withdrawal; p < 0.01). 29 patients (silymarin =
15, placebo = 14) died during the trial. Survival was not influenced
by sex, the persistence of alcohol intake, the severity of liver dys-
function or by the presence of alcoholic hepatitis in the liver biop-
sy. The authors also describe the frequency of complications at
the end of the observation period which was smaller in the sily-
marin than in the placebo group (p = 0.06). The frequency of en-
cephalopathy was not significantly lower in the silymarin-treated
population. 
1 small open trial [83] examined silymarin in patients with pri-
mary biliary cirrhosis and a suboptimal response to ursodeoxy-
cholic acid (UDCA). In 27 patients, additional oral silymarin
(140 mg tid) was given for 1 year. No significant changes in
serum enzymes nor the Mayo risk score were noted with the
combination therapy.
From these summaries, it is clear that only 2 of these 5 trials were
proper RCTs primarily set up to study mortality rates (Ferenci et
al. [78], Pares et al. [82]). The study by Bunout et al. [80] had the
same end-point but a low dose was used and it did not state if it
was properly blinded. The study by Trinchet [79] is relatively short
and half the studied population was not classified as cirrhotic;
since the deaths were not allocated to a diagnostic group, the en-
tire group of patients was considered ‘at risk’. The study by Velus-
si et al. [81] was retained in spite of being an open trial because
Table 3. Total mortality and liver-related mortality in trials with patients with cirrhosis taking silymarin ((Spalten bitte dezimal ausrichten am Punkt))
Author [ref] Child A/B/C Silymarin Continued alcohol Age, years Duration Patients Total mortality (%) Liver-related mortality (%)
Distrib. (%) (mg/day) (% of patients) (mean ± sd) months (n total)
  
silymarin placebo silymarin placebo sign. silymarin placebo sign.
Ferenci [78] 52 / 41 / 7 420 30 40 58 ± 12 24 170 32.20 47.00 0.056 18.40 37.30 0.007
Trinchet [79] 50 / 0 / 0* 420 50 51 51 ± 10 3 116 1.80 5.10 n.s. 1.80 5.10 n.s.
Bunout [80] No data 280 58 65 49 ± 3 15 71 14.70 13.50 n.s. 13.20 12.20 n.s.
Velussi [81] 100 / 0 / 0 600 0 0 63 ± 4 12 60 0.00 0.00 – 0.00 0.00 –
Pares [82] 33 / 60 / 7 450 38 29 50 ± 10 24 185 15.60 15.70 n.s. 9.40 14.60 n.s.
Total 44 / 30 / 4 280–600 37 38 54 ± 9 3–24 602 16.10 20.50 n.s. 10.00 17.30 0.01
OR silymarin : placebo (95% CI) 0.75 (0.49, 1.13) 0.53 (0.33, 0.86)
*50% Alcoholic hepatitis without cirrhosis.
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the 2 groups of diabetic patients were well balanced and, accord-
ing to the authors, had to abstain from alcohol for at least 2 years
prior to the study in order to be eligible. Note that there were no
deaths recorded in this study. 
Total Mortality
5 placebo RCTs in cirrhosis conducted with silymarin adequately
reported about mortality and, to an extent, about other details of
clinical interest (total: 602 patients; table 3). The dropout rates
were significantly higher in the silymarin-treated population
(21.3% vs. 14.3% with placebo, p < 0.05) mostly due to withdraw-
al of study consent in both groups. Total mortality was lower in
the silymarin-treated patients in 2 out of 5 trials, similar in 2, with
no mortality reported in the 5th trial. The overall difference of
–4.2% deaths (all trials pooled as reported, without correction for
duration of trial) did not attain the threshold of significance.
Other variables, such as percentage of patients abstaining from
alcohol may have influenced the outcomes but most of the trials
considered did not report results by covariates.
Liver-Related Mortality
In the studies analysed, the usual cause of ‘liver-related death’ as
defined by Khan et al. [84] was upper gastrointestinal bleeding
(UGB), hepatic failure or primary liver cell carcinoma. No deaths
were specifically attributed to spontaneous bacterial peritonitis
(SBP). 3 out of 5 trials reported a lower liver-related mortality
with the active treatment. Among the remaining studies, in the
trial by Bunout et al. [80], 9 out of 10 deaths were liver-related
without attribution to a therapeutic group, while there were no
deaths in the trial by Velussi et al. [81]. The pooled liver-related
mortality per year was 4.9% with silymarin and 9.3% with place-
bo. The overall liver-related mortality as reported in the trials
(without correction for duration) was 10% with silymarin and
17.3% with placebo, i.e. a reduction of 7.3% (p = 0.01). Sensitivity
analysis by random elimination of trials showed that the result
was not driven by any particular trial, but significance was depen-
dent on the study by Ferenci et al. [75] which contributed the
largest number of deaths. 
The overall (not corrected for trial duration) non-liver related
mortality was somewhat, but not significantly, higher in the sily-
marin-treated population (6.7%) than in the placebo-treated pop-
ulation (3.4%); this trend is mainly driven by the study of Pares et
al. [82].
Rates of Complications During Trials
None of the studies on cirrhosis carried out with silymarin consid-
ered clinical outcomes other than death as a primary end-point.
Based on the available data, several issues could be partially ex-
amined in the above mentioned studies. Different issues were
usually addressed in different trials; although these issues are in-
terrelated, they have to be regarded individually and cannot be
consolidated into one global picture.
Hospitalisations: Data about the need for hospitalisation during
the study were available from 3 studies. The following hospitalisa-
tions were rated as cirrhosis-related: (UGB), hepatic failure, he-
patic encephalopathy, ascites, SBP or primary liver cell carcinoma.
Non-related hospitalisations were not considered; that is, hospital-
isations after trauma or for hernial surgery. Most of the hospitali-
sations were for sclerotherapy due to oesophageal varices. 1 trial
[78] reported no hospitalisations, and the 2 remaining ones
showed fewer hospitalisations in the silymarin-treated popula-
tion, i.e. 25.0% of the silymarin-treated patients vs. 31.9% of the
placebo patients [80], and 6.3% vs. 13.5% [82], respectively. The
overall percentage of patients ever hospitalised was 10.0% for
silymarin vs. 16.9% for placebo (p = 0.086). 
UGB: Bleeding oesophageal varices constitute one of the most
serious complications of cirrhosis. Many factors associated with
decompensated cirrhosis increase the risk of UGB, including gen-
eral debility, coagulation defects and hepatic encephalopathy; the
size of the varix is also correlated with the risk of bleeding [85].
The total incidence of UGBs, both as a co-factor of death and as
‘last data’, was reported in the 2 largest trials: 4.6% with silymarin
vs. 9.6% with placebo [78], and 6.3% vs. 13.5% [82], respectively,
and showed a difference in favour of the active treatment (p =
0.042; Odds Ratio (OR) 0.44 (95% CI 0.20, 0.97)). However, the
number of patients having one or more episodes of UGB during
the study without fatal outcome in [82] was similar in the 2 groups
(placebo 7 cases, silymarin 5 cases). This finding suggests that the
decreased rate of UGBs reflects an overall improvement in the
patients, also evidenced by the lower liver-related mortality rate,
rather than being a direct (vascular) effect of silymarin.
Hepatocellular Carcinoma (HCC): HCC has not been investigat-
ed systematically in any of the trials, but in 2 trials it has been re-
ported as cause of death, and/or found at biopsy or at autopsy
(silymarin = 3.1%, placebo = 4.5% [82]; silymarin = 3.4%, placebo
= 7.1% [78]). Since in the latter study a similar number of patients
were autopsied in both groups, it seemed reasonable to pool and
compare the data with a descriptive purpose. Interestingly, in both
studies the incidence of HCC was lower in the silymarin-treated
population. 
Diabetes Mellitus in Patients with Chronic Liver Disease
The risk of diabetes is increased in patients with liver cirrhosis
due to hepatitis C or alcoholic liver disease [86]. Glucose intoler-
ance in cirrhosis results from 2 abnormalities that occur simulta-
neously: (1) insulin resistance of muscle and (2) an inadequate re-
sponse of the β-cells to appropriately secrete insulin in order to
overcome the defect in insulin action [87]. The prevalence of dia-
betes mellitus has been reported to be higher in HCV-related cir-
rhosis (23.6%) than in HBV-related [88] cirrhosis (9.4%). The
prevalence of diabetes mellitus is also closely associated with the
Child-Pugh score, increasing age and obesity [89]. However, the
cardiovascular and retinopathy risk is low in these patients [90].
The aim of the study by Velussi et al. [81] was to ascertain
whether long-term treatment with silymarin is effective in reduc-
ing lipoperoxidation and insulin resistance in diabetic patients
with cirrhosis. The efficacy parameters included fasting blood glu-
cose levels (at admission: 190 ± 14 mg/dl), mean daily blood glu-
cose levels (at admission: 202 ± 19 mg/dl), daily glucosuria levels
(at admission: 37 ± 12 g/day), glycosylated haemoglobin (HbA1c;
at admission: 7.9 ± 0.3%) and malondialdehyde levels (at admis-
sion: 2.2 ± 0.3 µmol/ml). There was a significant decrease in fast-
ing blood glucose levels and in fasting insulin levels (–40%) al-
ready after 4 months of treatment in the silymarin group, also
seen for mean daily blood glucose levels (–14.6%) and daily glu-
cosuria (–32%). However, the HbA1c levels at the end of the 12
months had diminished by 8.8%. In addition, there was a signifi-
cant decrease in the mean exogenous insulin requirements in the
treated group from 55 ± 5 IU/day to 45 ± 3 IU/day after 6 months
and 42 ± 2 IU/day after 12 months, while the untreated group
16 Forsch Komplementärmed 2008;15:9–20 Saller/Brignoli/Melzer/Meier
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 4
:0
2:
17
 P
M
Forsch Komplementärmed 2008;15:9–20Clinical Evidence of Silymarin 17
showed a significant increase in fasting insulin levels and a stabi-
lized insulin requirement. 
Similar results were reported by Lirussi et al. [91] with silybin-
beta-cyclodextrin (135 mg/day silibinin per os) in a placebo-con-
trolled, 6-month trial (admitted 60, finalized 42 patients). Fasting
blood glucose levels, which were similar at baseline in the silybin-
beta-cyclodextrin and in the placebo group decreased by –14.7%
vs. baseline in the silybin-beta-cyclodextrin group (p = 0.03 vs.
placebo). The same trend was observed in mean daily blood glu-
cose levels, HbA1c and insulin sensitivity (HOMA-IR), although
differences were not significant. Insulin secretion was virtually un-
affected. Plasma triglycerides concentrations dropped by 40% in
the silybin-beta-cyclodextrin group while they increased by 16%
in the placebo group, while total and HDL cholesterol as well as
liver function tests did not change significantly. However, the
weight of this study was limited by the small number of patients
participating, the large proportion of dropouts and the absence of
an ‘intent to treat’ analysis.
One small open trial [92] suggests similar effects in non-alcoholic
fatty liver disease with a silybin + vitamin E + phospholipids
preparation by improving insulin resistance and plasma levels of
markers of liver fibrosis.
Planned and Ongoing Trials
Several of the various leads derived from experimental pharma-
cology also have induced clinical trials, some of which have been
mentioned as planned in the literature: (1) pilot study of silymarin
in patients receiving hepatotoxic chemotherapy (National Cancer
Institute, NCI, USA, http://cancer.gov/search/viewclinicaltrials);
(2) study of botanical/drug interactions in HIV (National Center
for Complementary and Alternative Medicine, NCCAM; USA),
(3) IdB 1016 treatment for hepatitis C disease (NCCAM; USA),
(4) prevention of the serological recurrence of ovarian cancer
with IdB 1016 (Catholic University of the Sacred Heart; Rome,
Italy), (5) silibinin in phase I clinical trial in prostate cancer pa-
tients (University of Colorado Cancer Center; USA). Further-
more, in preparation, the silymarin Product Development Pro-
gram and the silymarin Research Network (NCCAM; and the Na-
tional Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) of the National Institutes of Health (NIH) and of the
Department of Health and Human Services (DHHS); USA).
Safety Data
The safety data of silymarin have been reviewed based on data
derived from clinical trials adequately reporting on safety provid-
ing a full list of AEs reported by the patients [55, 65, 66, 68, 69,
76–79] or from AEs spontaneously reported in the literature [93].
The safety of silymarin has been analysed ‘in extenso’ in an earli-
er paper [3] and will only merit a short chapter here (table 4).
In the clinical trials, neither deaths nor other serious AEs were at-
tributed to the therapy, and the incidence was slightly lower in the
silymarin than in the placebo-treated population. The incidence
of AEs justifying an interruption of treatment and of AEs in gen-
eral was very low and within the range of placebo values. In com-
parative studies the side effects with an incidence of ≥1% were
headaches (silymarin 1.01%; placebo 1.35%) and pruritus (sily-
marin 1.35%; placebo 3.70%). The side effects reported in open
silymarin trials showed a predominance of digestive symptoms
(diarrhoea 0.20%, irregular stools 0.10%, nausea 0.13%, dyspep-
sia 0.08%).
The spontaneously reported cases provided little information
concerning incidences of AEs but gave a better picture of rare
and usually more severe AEs. There were neither deaths nor life-
threatening events. Only 1 case deemed serious or potentially se-
rious was probably related to silymarin, i.e. a woman aged 57
years with intermittent episodes of sweating, nausea, colicky pain,
diarrhoea, vomiting, weakness and collapse was admitted to hos-
pital during 1 day; clinical examination and laboratory values
within normal range; rechallenge a few weeks later reproduced
symptoms (product: Aust L 56929; Optimum Healthcare Pty Ltd).
The authors considered that some component other than silibinin
could have been responsible. In 2 cases of urticaria / pruritus a
positive rechallenge was reported. 
Discussion and Conclusions
The biopharmaceutical problems related to silymarin-containing
products are very important, resulting in a wide range of plasma
levels following one same dose of different pharmaceutical prod-
ucts. A large proportion of the studies analyzed in this review
were performed with one well-standardised product (Legalon™)
but the results cannot be extrapolated to any silymarin-containing
preparation without checking the bioavailability data. Neither op-
timal nor maximal therapeutic doses have been defined so far
and, in view of the experimental data, they are likely to be indica-
tion dependent. In most of the trials, the reportedly effective daily
doses of silymarin were 420–600 mg (range: 280 mg/day, ‘not ef-
fective’ [80]; and 800 mg, ‘effective’ [44]. The experimental and
clinical evidence concerning the hepatologic indications of sily-
marin are summarised in figure 1 and have also been recently dis-
cussed in detail by a group of US experts [94].
In the opinion of the reviewers, the limited available evidence still
supports the use of silymarin in Amanita phalloides poisoning
(silibinin hemisuccinate i.v.). The reviewers were unable to draw a
valid conclusion on the use of silymarin in the therapy of other
toxic and iatrogenic liver diseases often associated with, or aggra-
vated by, an alcoholic problem. However, ‘no evidence of effect’ is
Controlled trials Silymarin,

silymarin placebo
open studies
Total number of patients 296 297 3612
Deaths, related to underlying disease, % 7.09 7.41 0.19
Interrupted trial (excluding deaths), % 0.68 0.67 0.17
Total patients with AEs, % 2.36 5.05 1.02
Table 4. Summary of AEs by seriousness, as
reported in the published clinical trials
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 4
:0
2:
17
 P
M
18 Forsch Komplementärmed 2008;15:9–20 Saller/Brignoli/Melzer/Meier
not ‘evidence of no effect’ [3]. The conclusions of the different
authors are favourable to the drug and (in view of its excellent
safety profile) the reviewers conclude that, for the time being, the
treating physician may consider the use of silymarin as part of a
treatment scheme in case of poisoning with drugs inducing lipid
peroxidation.
The situation is similar concerning its use in the therapy of acute
or chronic viral hepatitis, frequently a cause of cirrhosis, although
the negative results in hepatitis-C patients in Egypt are not neces-
sarily representative for Western countries (differences in nutri-
tion and absence of alcoholic intake). ‘There is no evidence that
silymarin affects viral load or improves liver histology in hepatitis
B or C. No studies were found that investigated the use of sily-
marin concomitantly with interferon, nucleoside analogues, or
other conventional treatments for hepatitis B or C. It may be
worthwhile to determine its effects in conjunction with standard
antiviral treatment’ [95]. Interestingly, it has been described in the
literature that in viral hepatitis, enzymatic improvements (partic-
ularly of ALT) which were the main end-points in some of the
silymarin trials, tend to under-reflect the degree of histological im-
provement [96]. 
Although more data are needed, it seems reasonable to employ
silymarin in the therapy of alcoholic liver disease, obviously as a
supportive element in the broader context of the management of
the alcoholic patient, especially after discontinuation of alcohol
intake. In the opinion of the reviewers, the available evidence sup-
ports the therapeutic use of silymarin in alcohol-induced liver dis-
eases, including liver cirrhosis. The limited evidence available
does not support its use in primary biliary cirrhosis.
The selection of cirrhosis studies retained herein, even if not fully
correct from a methodological perspective, probably has the ad-
vantage of reflecting different settings, thus rendering it closer to
clinical reality; that is, increasing the external validity of the analy-
sis. In the trials dealing with (alcoholic) liver cirrhosis, while the
reduction in total mortality does not reach the threshold of signif-
icance (reduced –4.2%, OR 0.75 (95% CI 0.5, 1.1)), the reduction
of liver-related mortality (i.e. due to hepatic failure and/or upper
digestive haemorrhage) is significant (reduced –7%, OR 0.54
(95% CI 0.3, 0.9)). Consistent with this findings, a recent
Cochrane review [97] stated that ‘liver-related mortality was sig-
nificantly reduced by milk thistle in all trials (Risk Reduction
(RR) 0.50, 95% CI 0.29, 0.88), but not in high-quality trials (RR
0.57, 95% CI 0.28, 1.19)’.
Some secondary end-points also yielded results in favour of the
silymarin therapy, such as number of patients requiring hospitali-
sation during the trial, number of patients with UGB, and possibly
number of patients with hepatic carcinomas. Obviously, these sec-
ondary variables are interwoven to some extent with the primary
variable and may help to explain the reduction in liver-related
mortality. Furthermore, they are likely to have an impact on the
QoL and use of medical resources by cirrhotic patients. Future
prospective trials should address these issues as well as other con-
founding factors such as persistence of ‘offending’ factors, doses
and characterisation of silymarin preparation administered, con-
comitant therapies or interventions and, last but not least, the
compliance of the patients. The reviewers conclude that, from a
pragmatic point of view and with the available evidence of possi-
ble risks/probable benefits, it is reasonable to employ silymarin
as a supportive element in the therapy of (alcoholic and grade
Child ‘A’) liver cirrhosis. 
The improvement in the management of cirrhosis associated dia-
betes reported by 2 groups (in 2 relatively small trials) was most
interesting and deserves to be confirmed in a larger context. It is,
however, somewhat disturbing that the improvement of the glyco-
sylated HbA1c levels vs. controls was very modest and did not
reach the threshold of significance vs. controls. 
Concerning the practical consequences of a meta-analysis, it is
clear that ‘the clinical application of results from meta-analyses to
the individual patient often remains a difficult matter of judg-
ment’ [98]. The limited positive and negative predictive value of
meta-analysis should be taken into consideration, e.g. in a large
analysis of the matter, the agreement between the meta-analyses
and large clinical trials was only fair [99]. The positive predictive
value of the meta-analyses was 68%, and the negative predictive
value 67%. However, the difference in point estimates between
the randomised trials and the meta-analyses was statistically sig-
nificant for only 5 of the 40 comparisons (i.e. 12%).
The analysis of the safety data available on silymarin confirms
that this compound is very safe. Rare cases of digestive troubles
and of allergic skin rashes have been reported. In the case of
treatment with high doses of silymarin in polymedicated patients,
the treating physician should be aware of the hypothetical possi-
ble interactions.
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